Optimizing Bispecific Antibody Expression Via Multi-Omics Analysis And Vector Redesign

Even when bispecific antibody designs share high sequence homology, their expression levels can vary drastically, creating significant manufacturability hurdles. A recent investigation into IgG-scFv formats revealed that hidden liabilities, such as specific ribosome pausing sites and suboptimal codon usage, can severely limit production even in otherwise promising candidates. By utilizing multi-omics analysis to diagnose these root causes, researchers engineered a revised variant that achieved an 11-fold increase in stable expression titers.
This case study highlights how integrating computational predictions with synthetic biology can effectively resolve expression bottlenecks and rescue complex biologics early in the development pipeline. Access the full analysis to understand how targeted sequence engineering can transform manufacturability.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.